@article{fdi:010064910,
  title = {{P}lasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate 300 mg every 48 hours vs 150 mg once daily in hiv-infected adults with moderate renal function impairment},
  author = {{C}ressey, {T}. {R}. and {A}vihingsanon, {A}. and {H}alue, {G}. and {L}eenasirimakul, {P}. and {S}ukrakanchana, {P}. {O}. and {T}awon, {Y}. and {J}aisieng, {N}. and {J}ourdain, {G}onzague and {P}odany, {A}. {T}. and {F}letcher, {C}. {V}. and {K}linbuayaem, {V}. and {B}owonwatanuwong, {C}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground. {T}he approved tenofovir disoproxil fumarate ({TDF}) dose of 300 mg every 48 hours for adults with moderate renal impairment is often confusing and inconvenient. {U}sing a new {TDF} formulation, we compared the pharmacokinetics of the standard dose with a dose of 150 mg once daily in {HIV}-infected adults. {M}ethods. {T}his was an open-label pharmacokinetic study. {V}irologically suppressed {HIV}-infected adults with a creatinine clearance 30 to <50 m{L}/minute receiving {TDF} 300 mg every 48 hours as part of a nonnucleoside reverse transcriptase inhibitor ({NNRTI})- or lopinavir/ritonavir ({LPV}/r)-based regimen were enrolled. {I}ntensive 48-hour blood sampling for pharmacokinetic assessment was performed at enrollment, after which the {TDF} dose was changed to 150 mg once daily. {T}wo weeks later, 24-hour blood sampling was performed; subjects then returned to the standard dose. {T}enofovir ({TFV}) pharmacokinetic parameters were calculated using a noncompartmental analysis. {R}esults. {F}orty adults (55% female) were enrolled: 20 receiving {NNRTI}-based and 20 receiving {LPV}/r-based treatment. {M}edian age was 56 years (range, 44-65 years), weight 51 kg (range, 38-80 kg), and creatinine clearance 43.9 m{L}/minute (range, 30.9-49.7 m{L}/minute). {T}he {TFV} geometric mean ratio of the area under the curve ({AUC}(0-48h)) for every 24 hours vs every 48 hours was 1.09 (90% confidence interval [ {CI}],.98-1.22) and 1.00 (90% {CI},.92-1.09) for patients receiving {NNRTI}- and {LPV}/r-based treatment, respectively. {C}oncomitant {LPV}/r use markedly increased {TFV} plasma concentrations, and {AUC}(0-48h) was 67% higher with the standard dose, whereas no differences in intracellular {TFV} diphosphate concentrations were observed. {A}ll subjects remained virologically suppressed, and no drug-related adverse events were reported. {C}onclusions. {TDF} 150 mg every 24 hours provides comparable systemic exposure to the standard dose of 300 mg every 48 hours in patients with moderate renal impairment.},
  keywords = {{HIV} ; tenofovir ; kidney dysfunction ; {THAILANDE}},
  booktitle = {},
  journal = {{C}linical {I}nfectious {D}iseases},
  volume = {61},
  numero = {4},
  pages = {633--639},
  ISSN = {1058-4838},
  year = {2015},
  DOI = {10.1093/cid/civ346},
  URL = {https://www.documentation.ird.fr/hor/fdi:010064910},
}